Last reviewed · How we verify
Atrovent
At a glance
| Generic name | Atrovent |
|---|---|
| Also known as | SAMA |
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Ipratropium Bromide on EILO (PHASE2)
- Magnesium Trial in Acute Asthma in Emergency Department (PHASE3)
- Functional Strength Training and Neuromuscular Electrical Stimulation in Severe Acute Exacerbations of COPD (NA)
- Revefenacin in Acute Respiratory Insufficiency in COPD (PHASE2)
- Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations (PHASE2)
- The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome (PHASE4)
- Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease (NA)
- Treating Respiratory Emergencies in Children Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |